ArticleFrontiers in immunology2019
Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Antiglycation approach in selected autoimmune diseases: Where do we stand?Redox biology · 2026Review
- RAGE-Mediated Signalling in Gynaecological Disorders: Review of Molecular Mechanisms and Therapeutic Perspectives.Expert reviews in molecular medicine · 2026Review
- HMGB1-Platelet Interactions: Mechanisms and Targeted Therapy Strategies.Thrombosis and haemostasis · 2026Review
- Wnt signaling as a translational target in rheumatoid and psoriatic arthritis.Journal of translational medicine · 2025Article
- Stretch Causes cffDNA and HMGB1-Mediated Inflammation and Cellular Stress in Human Fetal Membranes.International journal of molecular sciences · 2024Article
- Serum Advanced Glycation End Products and Their Soluble Receptor as New Biomarkers in Systemic Lupus Erythematosus.Biomedicines · 2024Article
- Efferocytosis by macrophages in physiological and pathological conditions: regulatory pathways and molecular mechanisms.Frontiers in immunology · 2024Review
- The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases.International journal of molecular sciences · 2023Review
- RAGE signaling regulates the progression of diabetic complications.Frontiers in pharmacology · 2023Review
- The role of monocytes in thrombotic diseases: a review.Frontiers in cardiovascular medicine · 2023Review
- Low-dose aspirin protects unexplained recurrent spontaneous abortionFrontiers in endocrinology · 2022Article
- HMGB1 in Pediatric COVID-19 Infection and MIS-C: A Pilot Study.Frontiers in pediatrics · 2022Article
- Platelets in the NETworks interweaving inflammation and thrombosis.Frontiers in immunology · 2022Review
- Article
- Cellular Response against Oxidative Stress, a Novel Insight into Lupus Nephritis Pathogenesis.Journal of personalized medicine · 2021Article
- High-mobility group box 1 is a driver of inflammation throughout pregnancy.American journal of reproductive immunology (New York, N.Y. : 1989) · 2021Review
- Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases.International journal of molecular sciences · 2020Review
- Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models.Frontiers in cardiovascular medicine · 2020Review
- Article
- Misunderstandings Between Platelets and Neutrophils Build in Chronic Inflammation.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disease characterized by arterial and/or venous thrombosis, pregnancy morbidity in the presence of circulating "anti-phospholipid antibodies" (aPL). One of the main target antigens of aPL is β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.